PMID- 38440729
OWN - NLM
STAT- MEDLINE
DCOM- 20240306
LR  - 20240405
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 15
DP  - 2024
TI  - Impacts of systemic inflammation response index on the prognosis of patients with 
      ischemic heart failure after percutaneous coronary intervention.
PG  - 1324890
LID - 10.3389/fimmu.2024.1324890 [doi]
LID - 1324890
AB  - BACKGROUND: Atherosclerosis and cardiovascular diseases are significantly 
      affected by low-grade chronic inflammation. As a new inflammatory marker, the 
      systemic inflammation response index (SIRI) has been demonstrated to be 
      associated with several cardiovascular disease prognoses. This study aimed to 
      investigate the prognostic impact of SIRI in individuals having ischemic heart 
      failure (IHF) following percutaneous coronary intervention (PCI). METHODS: This 
      observational, retrospective cohort study was conducted at a single site. 
      Finally, the research involved 1,963 individuals with IHF who underwent PCI, with 
      a 36-month follow-up duration. Based on the SIRI quartiles, all patients were 
      classified into four groups. Major adverse cardiovascular events (MACEs) were the 
      primary outcomes. Every element of the main endpoint appeared in the secondary 
      endpoints: all-cause mortality, non-fatal myocardial infarction (MI), and any 
      revascularization. Kaplan-Meier survival analysis was conducted to assess the 
      incidence of endpoints across the four groups. Multivariate Cox proportional 
      hazards analysis confirmed the independent impact of SIRI on both the primary and 
      secondary endpoints. The restricted cubic spline (RCS) was used to assess the 
      nonlinear association between the SIRI and endpoints. Subgroup analysis was 
      performed to confirm the implications of SIRI on MACE in the different subgroups. 
      RESULTS: The main outcome was much more common in patients with a higher SIRI. 
      The Kaplan-Meier curve was another tool that was used to confirm the favorable 
      connection between SIRI and MACE. SIRI was individually connected to a higher 
      chance of the main outcome according to multivariate analyses, whether or not 
      SIRI was a constant [SIRI, per one-unit increase, hazard ratio (HR) 1.04, 95% 
      confidence interval (95% CI) 1.01-1.07, p = 0.003] or categorical variable 
      [quartile of SIRI, the HR (95% CI) values for quartile 4 were 1.88 (1.47-2.42), p 
      <0.001, with quartile 1 as a reference]. RCS demonstrated that the hazard of the 
      primary and secondary endpoints generally increased as SIRI increased. A 
      non-linear association of SIRI with the risk of MACE and any revascularization 
      (Non-linear P <0.001) was observed. Subgroup analysis confirmed the increased 
      risk of MACE with elevated SIRI in New York Heart Association (NYHA) class III-IV 
      (P for interaction = 0.005). CONCLUSION: In patients with IHF undergoing PCI, 
      increased SIRI was a risk factor for MACE independent of other factors. SIRI may 
      represent a novel, promising, and low-grade inflammatory marker for the prognosis 
      of patients with IHF undergoing PCI.
CI  - Copyright (c) 2024 Ma, Wu, Sun, Huang, Zhang, Chen, Zhao, Zhao and Zhou.
FAU - Ma, Meishi
AU  - Ma M
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Wu, Kang
AU  - Wu K
AD  - Capital Medical University, Personnel Department, Beijing, China.
FAU - Sun, Tienan
AU  - Sun T
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Huang, Xin
AU  - Huang X
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Zhang, Biyang
AU  - Zhang B
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Chen, Zheng
AU  - Chen Z
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Zhao, Zehao
AU  - Zhao Z
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
FAU - Zhao, Jiajian
AU  - Zhao J
AD  - Department of Cardiology, Bengang General Hospital of Liaoning Health Industry 
      Group, Benxi, China.
FAU - Zhou, Yujie
AU  - Zhou Y
AD  - Department of Cardiology, Capital Medical University Affiliated Anzhen Hospital, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20240219
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Retrospective Studies
MH  - *Heart Failure/etiology
MH  - Prognosis
MH  - Inflammation
MH  - *Myocardial Infarction
PMC - PMC10910016
OTO - NOTNLM
OT  - MACE
OT  - ischemic heart failure
OT  - percutaneous coronary intervention
OT  - prognosis
OT  - systemic inflammation response index
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/05 06:45
MHDA- 2024/03/06 06:43
PMCR- 2024/01/01
CRDT- 2024/03/05 03:59
PHST- 2023/10/20 00:00 [received]
PHST- 2024/01/31 00:00 [accepted]
PHST- 2024/03/06 06:43 [medline]
PHST- 2024/03/05 06:45 [pubmed]
PHST- 2024/03/05 03:59 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2024.1324890 [doi]
PST - epublish
SO  - Front Immunol. 2024 Feb 19;15:1324890. doi: 10.3389/fimmu.2024.1324890. 
      eCollection 2024.